Can losartan 50 mg be initiated in a 77‑year‑old former smoker with normal blood pressure, preserved left ventricular ejection fraction, grade I diastolic dysfunction, mild pulmonary hypertension, and no bradycardia, severe asthma, or hypotension?

Can You Start Losartan 50 mg?

Yes, you can initiate losartan 50 mg in this 77-year-old patient with normal blood pressure, preserved ejection fraction, grade I diastolic dysfunction, and mild pulmonary hypertension, but only if there is a clear indication for angiotensin receptor blocker therapy beyond blood pressure control. 1

Key Considerations Before Initiation

Blood Pressure Status

• The patient currently has normal blood pressure, which raises the question of whether losartan is indicated at all. 1
• Losartan is FDA-approved for hypertension, hypertensive patients with left ventricular hypertrophy, and nephropathy in type 2 diabetic patients—none of which clearly apply to this normotensive patient. 1
• If blood pressure is truly normal (systolic <130 mmHg and diastolic <80 mmHg), starting an antihypertensive agent risks inducing hypotension, particularly in an elderly patient. 2

Diastolic Dysfunction and Preserved Ejection Fraction

• Grade I diastolic dysfunction with preserved ejection fraction does not constitute a clear indication for losartan monotherapy. 3
• While angiotensin receptor blockers have been studied in heart failure with preserved ejection fraction (HFpEF), the ELITE II trial showed no mortality benefit for losartan compared to captopril in heart failure patients, and the I-PRESERVE and CHARM-Preserved trials failed to demonstrate improved morbidity and mortality with ARBs in HFpEF. 3, 4
• The LIFE study did show reduced heart failure hospitalization in hypertensive patients with normal in-treatment diastolic function, but this benefit was in the context of treating hypertension, not isolated diastolic dysfunction. 3

Mild Pulmonary Hypertension

• The mild pulmonary hypertension in this patient is likely post-capillary (Group 2 PH-LHD) given the presence of diastolic dysfunction. 5, 6
• Losartan is not a specific therapy for pulmonary hypertension; PAH-specific drugs (prostaglandins, endothelin receptor antagonists, phosphodiesterase inhibitors) are used for pre-capillary PAH, not post-capillary PH due to left heart disease. 7, 5
• In the PARAGON-HF echocardiographic substudy, 31% of HFpEF patients had pulmonary hypertension, but ARB therapy was not specifically beneficial for this finding. 6

Dosing Guidance If Initiation Is Appropriate

Standard Starting Dose

• The FDA-approved starting dose for losartan in adult hypertension is 50 mg once daily, which can be increased to a maximum of 100 mg daily as needed. 1
• However, a 25 mg starting dose is recommended for patients with possible intravascular depletion (e.g., those on diuretic therapy) or hepatic impairment. 1
• In elderly patients, the 50 mg dose has been shown to be safe and effective, with adverse event rates of only 0.2% in a large observational study of 4,599 patients (mean age 61 years). 8

Titration Strategy

• If blood pressure response is inadequate after starting at 50 mg, the dose can be increased to 100 mg once daily. 1, 8
• In the NCT-CZ 14/04/LOZ study, 87% of patients were maintained on the 50 mg dose throughout the 6-month study period, suggesting this dose is often sufficient. 8

Monitoring Requirements

Blood Pressure and Heart Rate

• Measure sitting and standing blood pressures before initiation to screen for orthostatic hypotension, which is particularly important in elderly patients. 9
• Recheck blood pressure 2–4 weeks after starting therapy. 9
• Avoid lowering diastolic blood pressure below 60 mmHg in patients with potential coronary artery disease (common in elderly patients), as this may worsen myocardial perfusion. 2

Renal Function and Electrolytes

• Check serum potassium and creatinine at baseline and within 1–2 weeks of starting losartan, particularly if the patient is on other medications that affect potassium (diuretics, spironolactone). 10
• No dosage adjustment is required for mild to moderate renal dysfunction, but monitoring is essential. 11

Common Pitfalls to Avoid

• Starting losartan without a clear indication: In a normotensive patient without diabetes, nephropathy, or uncontrolled hypertension, the benefit-risk ratio may not favor initiation. 1, 3
• Ignoring orthostatic hypotension risk: Elderly patients are at higher risk for symptomatic hypotension, especially if volume-depleted. 1, 11
• Expecting improvement in diastolic function: While losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction, it does not consistently improve Doppler parameters of diastolic function (E/A ratio, isovolumic relaxation time). 12
• Assuming benefit for pulmonary hypertension: Losartan is not indicated for pulmonary hypertension management; if PH is significant, referral to a pulmonary hypertension specialist is appropriate. 7, 5

Alternative Considerations

• If the goal is to address diastolic dysfunction and mild pulmonary hypertension in the context of preserved ejection fraction, consider whether any therapy is needed at all given the lack of proven benefit in this population. 3, 4
• If hypertension develops or is borderline, losartan 50 mg is a reasonable first-line agent, particularly if the patient has left ventricular hypertrophy on echocardiography. 1, 11
• For patients with more advanced heart failure symptoms, sacubitril/valsartan (ARNI) has emerging evidence in HFpEF and pulmonary hypertension, though it should be started at very low doses (25 mg twice daily) in elderly patients. 2, 5